133 related articles for article (PubMed ID: 34312841)
1. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
Alcoceba M; García-Álvarez M; Chillón MC; Jiménez C; Medina A; Antón A; Blanco O; Díaz LG; Tamayo P; González-Calle V; Vidal MJ; Cuello R; Díaz Gálvez FJ; Queizán JA; Martín A; González M; García-Sanz R; Sarasquete ME
Br J Haematol; 2021 Nov; 195(4):542-551. PubMed ID: 34312841
[TBL] [Abstract][Full Text] [Related]
2. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.
Camus V; Viennot M; Lequesne J; Viailly PJ; Bohers E; Bessi L; Marcq B; Etancelin P; Dubois S; Picquenot JM; Veresezan EL; Cornic M; Burel L; Loret J; Becker S; Decazes P; Lenain P; Lepretre S; Lemasle E; Lanic H; Ménard AL; Contentin N; Tilly H; Stamatoullas A; Jardin F
Haematologica; 2021 Jan; 106(1):154-162. PubMed ID: 32079702
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA in Hodgkin lymphoma.
Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.
Lebofsky R; Decraene C; Bernard V; Kamal M; Blin A; Leroy Q; Rio Frio T; Pierron G; Callens C; Bieche I; Saliou A; Madic J; Rouleau E; Bidard FC; Lantz O; Stern MH; Le Tourneau C; Pierga JY
Mol Oncol; 2015 Apr; 9(4):783-90. PubMed ID: 25579085
[TBL] [Abstract][Full Text] [Related]
9. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
10. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
Camus V; Viennot M; Lévêque E; Viailly PJ; Tonnelet D; Veresezan EL; Drieux F; Etancelin P; Dubois S; Stamatoullas A; Tilly H; Bohers E; Jardin F
Leuk Lymphoma; 2022 Apr; 63(4):834-844. PubMed ID: 35075971
[TBL] [Abstract][Full Text] [Related]
12. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
13. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
14. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
16. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
Camus V; Stamatoullas A; Mareschal S; Viailly PJ; Sarafan-Vasseur N; Bohers E; Dubois S; Picquenot JM; Ruminy P; Maingonnat C; Bertrand P; Cornic M; Tallon-Simon V; Becker S; Veresezan L; Frebourg T; Vera P; Bastard C; Tilly H; Jardin F
Haematologica; 2016 Sep; 101(9):1094-101. PubMed ID: 27479820
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
[TBL] [Abstract][Full Text] [Related]
19. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
20. [Current situation and prospect of breast cancer liquid biopsy].
Zhou B; Xin L; Xu L; Ye JM; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
